Maryland State Retirement & Pension System Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Maryland State Retirement & Pension System bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 64,386 shares of the company's stock, valued at approximately $1,557,000.

A number of other institutional investors also recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. raised its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, US Bancorp DE boosted its holdings in shares of Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 0.9 %

NYSE:HIMS traded down $0.35 on Tuesday, reaching $37.06. The stock had a trading volume of 17,491,541 shares, compared to its average volume of 13,934,664. The company has a 50-day moving average of $39.66 and a 200 day moving average of $29.22. The stock has a market cap of $8.23 billion, a P/E ratio of 84.23 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HIMS. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Citigroup reissued a "sell" rating and set a $27.00 target price on shares of Hims & Hers Health in a research report on Thursday, March 6th. Finally, Piper Sandler lifted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $37.31.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares of the company's stock, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company's stock, valued at approximately $4,712,033.25. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 998,244 shares of company stock valued at $35,662,485. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.